Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

Ei­sai and Bio­gen will price their new Alzheimer’s treat­ment Leqem­bi at $26,500 per year, US CEO Ivan Che­ung tells End­points News. With out­cries over the pric­ing of the drug­mak­ers’ pre­vi­ous drug, Aduhelm, all eyes are on the stick­er price for the duo’s new treat­ment cleared by the FDA on Fri­day.

Leqem­bi will like­ly be in­fused in few pa­tients at this stage, as the US gov­ern­ment’s in­sur­er for those over the age of 65 puts a lim­it on cov­er­age of an­ti-amy­loid drugs fol­low­ing the Aduhelm nod. Pa­tients es­sen­tial­ly have to be in a clin­i­cal tri­al to get cov­er­age from the Cen­ters for Medicare & Med­ic­aid Ser­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER